Related Experiment Video
Updated: Jul 23, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy
Z Varghese1, J F Moorhead, X Z Ruan
1Centre for Nephrology, Royal Free and University College Medical School, University College London, London, UK. z.varghese@medsch.ucl.ac.uk
Abstract:
Fibrate peroxisome proliferator-activated receptor (PPAR)-alpha ligands are mainly used as hypolipidemic drugs. But this commentary highlights their potential in treating insulin resistance, dyslipidemia, and hypertension and in preventing diabetic nephropathy, inflammation, and cardiovascular disease. Because diabetes is a major contributor to chronic kidney disease and cardiovascular disease, PPAR-alpha agonists may provide greater opportunities for hitting multiple targets in this complex metabolic disease.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
06:50Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
Published on: September 5, 2025
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Antihypertensive Drugs: Direct Renin Inhibitors
Pharmacogenomics: Identification of New Drug Targets
Dipeptidyl Peptidase 4 Inhibitors
Diabetic Retinopathy
Diabetic Nephropathy